Breaking News – Ovarian Cancer Research Dream Team Selected

April 21, 2015

Board President (far left) Samantha Lockwood and Collaborating Partners

Board President (far left) Samantha Lockwood and Collaborating Partners

Stand Up to Cancer Ovarian Cancer Dream Team Announced

The American Association for Cancer Research (AACR), Scientific Partner to SU2C, announced today the formation of a Dream Team devoted to ovarian cancer research at the AACR Annual Meeting 2015, held in Philadelphia.

HERA Women’s Cancer Foundation is contributing $200,000 to this effort because of your support. Thank you. This is an opportunity that will have great impact for the ovarian cancer community as a whole, and we are thrilled to be one of the organizations collaborating in this effort. For the thousands of women and families affected by ovarian cancer who are looking to the world of science for answers, innovative research is the best hope for achieving better outcomes.

Our focus at HERA Women’s Cancer Foundation is eliminating ovarian cancer by funding scientific research grants. The Stand Up to Cancer Ovarian Cancer collaborative effort allows HERA to better leverage every dollar raised for this partnership. Our participation in this effort would not be possible without you. Thank you for your unwavering support in what we do. Your support means the world to every life that has been affected by this insidious disease.

I hope you will share this news with family and friends who have supported us and take pride in our accomplishments together.   Read on…

Collaborating organizations, including HERA, will collectively devote $6 million over three years to a project entitled “DNA Repair Therapies for Ovarian Cancer.” The U.S. Food and Drug Administration (FDA) last year approved the drug olaparib to treat women with advanced ovarian cancer associated with defective BRCA genes, which are among a number of DNA repair genes identified as mutated in ovarian cancer. The existence of defects in DNA repair has emerged as a common weakness in ovarian cancer. By targeting DNA repair pathways, the Dream Team hopes to build and expand on the recent clinical advances seen with olaparib and other PARP inhibitors in current clinical trials.

The team will also focus on prevention and early detection of ovarian cancer, which tends to be diagnosed at a late stage of the disease.

Alan D’Andrea, MD, co-director of the Gene Therapy Center at Dana-Farber Cancer Institute in Boston, and the Fuller-American Cancer Society professor of medicine at Harvard Medical School, will lead the Dream Team. Elizabeth M. Swisher, MD, professor in the Department of Obstetrics and Gynecology at the University of Washington in Seattle, will be co-leader.

In addition to the team leaders, the project will involve researchers at Mayo Clinic in Rochester, Minnesota; University of Chicago; The University of Texas MD Anderson Cancer Center in Houston; and Memorial Sloan Kettering Cancer Center in New York.

Thank you for your unwavering support!

Full Press Release

Comments

Your email is used for verification purposes only, it will never be shared.

news image strip